Sentences with phrase «for tumor therapy»

Not exact matches

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

Because the tumor chips can be printed, essentially, in unlimited supply, the possibility for fine - tuning a drug therapy is endless.

«This approval will open the floodgates for these kinds of therapy to be used in many different leukemias, lymphomas, solid tumors, myelomas,» Dr. Prakash Satwani, a pediatric hematologist - oncologist at Columbia University Medical Center, told Business Insider.

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

Cambridge, MA — March 5, 2015 — Aura Biosciences, a biotech company developing highly tumor - targeted breakthrough therapies for rare cancers, has secured a $ 21M Series B round of funding.

Our pipeline currently includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.

Around four - fifths of prostate cancer patients have tumors with lots of PSMA for the therapy to bind to.

The FDA approved a Lutetium - 177 based cancer therapy called Lutathera for the treatment of neuroendocrine tumors earlier this year, after Novartis snapped up the developer, Advanced Accelerator, at a premium.

For instance, most common adult solid tumors that are not cured by surgical removal are resistant to chemotherapy or radiation control, yet drug therapy is frequently offered as a «possibly effective» treatment because both patient and physician want to believe it so.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

This method, sometimes called «liquid biopsy,» can provide guidance for treatment decisions, monitoring of cancer therapy, and organism - wide screening for the presence of nascent metastatic tumors in drug - treated cancer patients.

The Moores Cancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theraTumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theratumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard therapies.

In melanoma, they can be used to determine tumor stage, diagnosis, therapy selection and when to monitor for disease recurrence.

«Next generation sequencing tools were used to profile patients» tumors,» said Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at UC San Diego Moores Cancer Center.

A route used by tumor cells to spread could be exploited to make stem cells for regenerative medicine and cancer therapies

«Combination therapy strengthens T cells in melanoma pre-clinical study: Findings have implications for treating tumors lacking tumor suppressor gene PTEN.»

Currently, many patients who acquire resistance to EGFR - targeted therapy undergo a tumor biopsy and are designated as either positive or negative for specific secondary mutations.

«For patients who have not responded to prior therapies, this drug now provides a very real chance to shrink their tumors and the hope of a lasting response to treatment.»

«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.

The authors suggest that therapies targeting TP53 mutations may yield better clinical outcomes for patients with HPV - inactive tumors.

The scientists also tested the therapy on tumors taken from two patients who had not responded to conventional therapy for their glioblastoma, a deadly form of brain cancer.

Researchers compared two common postsurgical therapies for metastatic brain tumors and found that stereotactic radiosurgery can provide better outcomes for patients compared to whole - brain radiation.

«Given the devastating impact of cancer metastasis and the dire need for therapies to combat tumor spread, we're highly encouraged by these findings and excited about the therapeutic possibilities they open up.»

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

No targeted therapy has been approved for noninflammatory and inflammatory triple - negative breast cancer tumors, and the standard of therapy for these tumors is a combination of conventional cytotoxic chemotherapeutic agents.

This is particularly true for immunotherapy, in which characterization of tumor heterogeneity is essential for choosing the most effective therapy.

The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.

«Considering that PDPN is associated with poor prognosis in GBM, CAR T - cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first - line chemotherapy,» says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine.

To acquire new insights into the biology and possible therapy of these tumors, Feigin et al. looked for aberrant expression of G protein — coupled receptors, cell signaling proteins that have been successfully targeted for treatment of other disorders such as depression.

EM: Imaging such as MRIs or CT scans, which reveal the mass and volume of the tumor, can fool you sometimes: The patient gets a scan, goes on a therapy, and when they return in a month for a second imaging, the structure and size of the tumor haven't changed.

This did confound the field for a while because with traditional therapies an expanding tumor is a sign of failure.

«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»

These cancer stem cells act like the seeds of cancer and are responsible for re-growing a tumor after therapy.

Conventional therapies target rapidly dividing tumor cells, but are unable to eradicate the highly chemoresistant tumor initiating cells (TICs), ultimately responsible for relapse and spreading of the tumors in other parts of the body.

«Overall, survival for patients with recurrent rhabdomyosarcoma is just 17 percent, and until now nothing was known about how tumors evolve in response to therapy,» said corresponding author Michael Dyer, Ph.D., a member of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute Investigator.

Chitayat wonders whether proliferation could proceed in unexpected ways, for example leading to tumors — a worry that cuts across many stem cell therapies.

«We are looking to optimize the combinations of targeted therapies and the scheduling of those therapies so we can improve tumor shrinkage and minimize potential toxicities for a patient,» said Andrew Aplin, PhD, Associate Director for Basic Research and the Program Leader for Cancer Cell Biology and Signaling (CCBS) in the NCI - designated Sidney Kimmel Cancer Center at Jefferson Health.

«New targeted therapy schedule could keep melanoma at bay: Optimizing the timing of targeted therapies for melanoma reverses tumor growth, and resistance can be mitigated..»

«This indicates that therapies for high - grade gliomas should be personalized, that is, based on the tumor subtype instead of applying one treatment to all patients,» he says.

Glioblastoma accounts for about 15 percent of all brain tumors, is resistant to current therapies and has a survival as short as 15 months after diagnosis.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

Following cancer therapy, the dominant cells may die first, and other cells that were originally not as fit may find themselves better able to compete for necessary space and nutrients and continue to grow and take over the tumor.

«Thanks to a deeper understanding of cancer biology, we have a potential new targeted therapy for multiple myeloma, and can better tailor treatment for kids with Wilms tumor.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

Little is known, however, about the metabolic pathways that drive the growth of individual glioblastoma subtypes — knowledge that is crucial for developing novel and effective targeted therapies that might improve treatment for these lethal tumors.

To find the best therapy for each one of these 33 tumor facets, the researchers tested about 180 different active substances.

«Though many challenges still remain, such work could potentially transform treatment outcomes for patients with glioblastoma and related brain tumors, for which current therapies provide limited benefits.»

I'm interested in doing a film on proton therapy, for example, because I have a tumor in my brain; it's the tumor that affected my eyesight as a child.

The new strategy calls for administering drugs before surgery — usually doctors do surgery first — and precisely imaging the tumors» response before moving on to extended drug therapy.

EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available.